Navigation Links
Cornerstone Therapeutics Reports Year Ended December 31, 2008 Financial Results
Date:3/26/2009

uipment, net 895 209 Product rights, net 17,702 4,936 Goodwill 13,231 - Amounts due from related parties 38 29 Deposits 46 33 Total assets $69,889 $15,909 Liabilities and Stockholders' Equity (Deficit) Current liabilities: Accounts payable $10,288 $2,214 Accrued expenses 19,052 11,092 Current portion of license agreement liability 2,543 647 Line of credit - 1,750 Income taxes payable 2,937 130 Total current liabilities 34,820 15,833 Long-term liabilities: License agreement liability, less current portion 2,313 2,959 Note payable, related party - 9,412 Deferred income tax liability 3,330 - Total long-term liabilities 5,643 12,371 Total liabilities 40,463 28,204 Commitments and contingencies Stockholders' equity (deficit) Preferred stock - $0.001 par value, 5,000,000 shares authorized; no shares issued and outstanding - - Common stock - $0.001 par value, 90,000,000 shares authorized; 12,023,747 and 5,934,496 shares issued and outstanding as of December 31, 2008 and December 31, 2007, respectively 12 6 Additional paid-in capital 33,519 797 Accumulated deficit
'/>"/>
SOURCE Cornerstone Therapeutics Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Cornerstone Therapeutics to Host Quarter and Year Ended December 31, 2008 Conference Call
2. Cornerstone Therapeutics Provides Update on Integration Activities and Issues 2008 Revenue Guidance
3. Cell Therapeutics, Inc. Reports Outcome of Special Meeting of Shareholders
4. Cell Therapeutics, Inc. Special Meeting in Lieu of Annual Meeting of Shareholders Scheduled for Tuesday, March 24, 2009
5. Cell Therapeutics Announces Filing of Form 10-K
6. Horizon Therapeutics Selected to Present at InsideVentures Debut Investor Conference March 25-26, Santa Barbara, California
7. Oxygen Biotherapeutics, Inc. Expands Board of Directors
8. Micromet Adds Sir Walter Bodmer and Bernard Fox to Its Advisory Panel for BiTE Antibody Therapeutics
9. Cell Therapeutics Presents Corporate Highlights at Invest Northwest Conference
10. Nile Therapeutics Announces Information in Compliance With NASDAQ Marketplace Rule 4350 and Reiterates 2009 Objectives
11. Medarex to Present at the Needham Cancer Therapeutics Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Dec. 24, 2014  United Therapeutics Corporation (NASDAQ: ... MDT ) has submitted a pre-market approval application ... the use of Medtronic,s SynchroMed ® II implantable ... use with United Therapeutics, Remodulin ® (treprostinil) Injection ...
(Date:12/24/2014)... 2014  Vermillion, Inc. (Nasdaq:   VRML), a bio-analytical ... that the Company closed its previously announced private ... Jack W. Schuler , Birchview Fund LLC and ... before offering expenses.  The proceeds will be used ...
(Date:12/24/2014)... December 23, 2014 “Preparative & ... HPLC, Flash), Consumables (Columns, Solvents, Buffers, Valves, Guages, ... & Agriculture) - Forecasts to 2019” provides a ... opportunities, current market trends, and strategies impacting the ...
(Date:12/24/2014)... Boston, MA (PRWEB) December 23, 2014 Earlier ... James L. Sherley, director of the Adult Stem Cell Technology ... overlooked and under appreciated unique property of adult tissue stem ... Misunderstood in the Past, Important for the Future,” embodied the ...
Breaking Biology Technology:United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4Vermillion Announces Closing of Equity Financing 2Vermillion Announces Closing of Equity Financing 3Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 2Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 3Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 4Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4
... 2011  Synergy Pharmaceuticals, Inc. (Nasdaq: SGYPD, SGYPU), a developer of ... today that it has filed a lawsuit in New York ... IRWD ) and its Chief Scientific Officer and Senior VP ... lawsuit alleges that after European patent 1,379,224 was granted to ...
... (Nasdaq: SGMO ) announced the presentation of new ... in an adult mouse model of hemophilia B using systemic ... Meeting of the American Society of Hematology (ASH). ... the clotting factor, Factor IX, with a single, systemic administration ...
... The Pharmabiotic Research Institute (PRI) brings together industrial and ... is a unique scientific and regulatory association in Europe. ... traditional food processing applications, probiotics can also be active ... why PRI uses the terminology "Pharmabiotics", relating to "LBP ...
Cached Biology Technology:Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie 2Sangamo BioSciences Announces Presentation of New Data from ZFP Therapeutic® Program in Hemophilia B at American Society for Hematology Meeting 2Sangamo BioSciences Announces Presentation of New Data from ZFP Therapeutic® Program in Hemophilia B at American Society for Hematology Meeting 3Sangamo BioSciences Announces Presentation of New Data from ZFP Therapeutic® Program in Hemophilia B at American Society for Hematology Meeting 4The Pharmabiotic Research Institute (PRI) is Preparing to Publish its First Works on the Therapeutic and Medicinal Potential of Probiotics 2The Pharmabiotic Research Institute (PRI) is Preparing to Publish its First Works on the Therapeutic and Medicinal Potential of Probiotics 3The Pharmabiotic Research Institute (PRI) is Preparing to Publish its First Works on the Therapeutic and Medicinal Potential of Probiotics 4
(Date:1/22/2015)... 15, 2015  BellBrook Labs, a leader in high ... launch of a TR-FRET (time resolved Forster resonance ... Assay, a high throughput screening assay for glycosyltransferases ... allow for sensitive detection of hundreds of human ...
(Date:1/22/2015)... , Jan. 20, 2015 NXT-ID, Inc. (NASDAQ: NXTD ... market, reports on the recent success of the Wocket™ smart wallet at ... Wocket smart wallet was named as one of the "11 Hot Products ... Best Products Launched At CES So Far" by Newseveryday.com and "The top ...
(Date:1/22/2015)... Issued by Small Cap IR. In 2011, Nilson Report,s annual ... merchants on the leading payment cards rose to $135.3 billion ... prepaid cards reached 6.54 billion.  Eight million credit card users ... 2012, and credit and debit card fraud resulted in $11.27 ...
Breaking Biology News(10 mins):BellBrook Labs Launches a High Throughput Screening Assay for Glycosyltransferases with TR-FRET Readout 2CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 2CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 3$4.80 Near Term Price Target with "Buy" given by CapRock Research for NXT-ID, Inc. (NASDAQ: NXTD) issued by Small Cap IR 2
... Finding cures for hearing loss, breast cancer and childhood ... for tuberculosis are goals of the first recipients of ... Collaborative Research Fund. The fund, a $3 million initiative ... supports collaboration among researchers at Rice University, Texas Children,s ...
... three undergraduates set off on an expedition in 1965 to ... realise that they were establishing the groundwork for a study ... led by the University of York has repeated the survey ... moved uphill by about 67 metres over the intervening years ...
... COLUMBIA, Mo. When it is head versus heart, ... organ to develop and is critical in supplying blood ... known about the complex processes that regulate the heartbeat. ... has identified certain proteins within the heart muscle that ...
Cached Biology News:Texas Medical Center researchers win collaborative grants 2Texas Medical Center researchers win collaborative grants 3Texas Medical Center researchers win collaborative grants 4The global impact of climate change on biodiversity 2Researchers examine developing hearts in chickens to find solutions for human heart abnormalities 2
Rab 3 Immunogen: Synthetic peptide corresponding to the N-terminal region of Rab 3 protein. Storage: -20 C, Avoid Freeze/Thaw Cycles...
...
Mouse monoclonal [2G1] to Vancomycin ( Abpromise for all tested applications)....
Rab1A...
Biology Products: